Abstract：
BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been used to diagnose and stage lung cancer. Acquire™ Pulmonary and Expect™ Pulmonary dedicated EBUS-TBNA needles were introduced as the Franseen and Lancet needles, respectively. It is still unclear whether the Franseen or Lancet needles yield a higher quality specimen especially focusing on next-generation sequencing-based molecular testing.
METHODS: A single-center, prospective study performed at the Chiba University Hospital randomly assigned patients to two groups: Group A, wherein the first and second EBUS-TBNA were performed using Lancet and Franseen needles, respectively, and Group B, wherein the first and second EBUS-TBNA were performed using Franseen and Lancet needles, respectively. Each specimen was compared and analyzed pathologically. The primary outcome was the histological tissue area except blood clot and the cellularity of each sample. We also examined the success rate of molecular testing.
RESULTS: Twelve patients who underwent EBUS-TBNA between November 2022 and February 2023 were enrolled in this study. The tissue area of the specimens obtained by the Franseen and Lancet needles was 13.3 ± 6.4 mm2 and 10.6 ± 6.3 mm2, respectively (P = .355). The tumor cellularity in the specimens obtained using the Franseen and Lancet needles was 54.0 ± 30.3 and 46.2 ± 36.3%, respectively (P = .608). The success rate of molecular testing using the single-pass sample by Franseen needle was 85.7 and 57.1% by Lancet needle. No serious complications were reported.
CONCLUSIONS: The Franseen needle tended to show a greater amount of specimen with higher tumor cellularity than the Lancet needle which may contribute higher success rate of molecular testing. Further studies must be conducted to validate the results of this study.
RESULTS: What is known and what is new? What is the implication, and what should change now?
METHODS: A single-center, prospective study performed at the Chiba University Hospital randomly assigned patients to two groups: Group A, wherein the first and second EBUS-TBNA were performed using Lancet and Franseen needles, respectively, and Group B, wherein the first and second EBUS-TBNA were performed using Franseen and Lancet needles, respectively. Each specimen was compared and analyzed pathologically. The primary outcome was the histological tissue area except blood clot and the cellularity of each sample. We also examined the success rate of molecular testing.
RESULTS: Twelve patients who underwent EBUS-TBNA between November 2022 and February 2023 were enrolled in this study. The tissue area of the specimens obtained by the Franseen and Lancet needles was 13.3 ± 6.4 mm2 and 10.6 ± 6.3 mm2, respectively (P = .355). The tumor cellularity in the specimens obtained using the Franseen and Lancet needles was 54.0 ± 30.3 and 46.2 ± 36.3%, respectively (P = .608). The success rate of molecular testing using the single-pass sample by Franseen needle was 85.7 and 57.1% by Lancet needle. No serious complications were reported.
CONCLUSIONS: The Franseen needle tended to show a greater amount of specimen with higher tumor cellularity than the Lancet needle which may contribute higher success rate of molecular testing. Further studies must be conducted to validate the results of this study.
RESULTS: What is known and what is new? What is the implication, and what should change now?
摘要：
背景：支气管内超声引导下经支气管针吸活检术（EBUS-TBNA）已用于肺癌的诊断和分期。Acquire™肺部和Expect™肺部专用EBUS-TBNA针头作为Franseen和Lancet针头引入，分别。尚不清楚Franseen或Lancet针头是否能产生更高质量的样本，尤其是专注于基于下一代测序的分子测试。
方法：单中心，在千叶大学医院进行的前瞻性研究将患者随机分为两组：A组，其中第一和第二EBUS-TBNA使用柳叶刀和弗兰塞针进行，分别,B组,其中第一和第二EBUS-TBNA使用Franseen和Lancet针进行，分别。对各标本进行病理对比分析。主要结果是除了血凝块和每个样品的细胞数量之外的组织学组织面积。我们还检查了分子测试的成功率。
结果：本研究纳入了2022年11月至2023年2月期间接受EBUS-TBNA的12例患者。通过Franseen和Lancet针获得的标本的组织面积分别为13.3±6.4mm2和10.6±6.3mm2（P=.355）。使用Franseen和Lancet针获得的标本中的肿瘤细胞率为54.0±30.3和46.2±36.3％，分别（P=.608）。使用Franseen针的单次通过样品进行分子检测的成功率分别为85.7％和Lancet针的57.1％。无严重并发症报告。
结论：与柳叶刀针相比，Franseen针倾向于显示更大量的肿瘤细胞性标本，这可能有助于更高的分子检测成功率。必须进行进一步的研究以验证本研究的结果。
结果：什么是已知的，什么是新的？含义是什么，现在应该改变什么？
方法：单中心，在千叶大学医院进行的前瞻性研究将患者随机分为两组：A组，其中第一和第二EBUS-TBNA使用柳叶刀和弗兰塞针进行，分别,B组,其中第一和第二EBUS-TBNA使用Franseen和Lancet针进行，分别。对各标本进行病理对比分析。主要结果是除了血凝块和每个样品的细胞数量之外的组织学组织面积。我们还检查了分子测试的成功率。
结果：本研究纳入了2022年11月至2023年2月期间接受EBUS-TBNA的12例患者。通过Franseen和Lancet针获得的标本的组织面积分别为13.3±6.4mm2和10.6±6.3mm2（P=.355）。使用Franseen和Lancet针获得的标本中的肿瘤细胞率为54.0±30.3和46.2±36.3％，分别（P=.608）。使用Franseen针的单次通过样品进行分子检测的成功率分别为85.7％和Lancet针的57.1％。无严重并发症报告。
结论：与柳叶刀针相比，Franseen针倾向于显示更大量的肿瘤细胞性标本，这可能有助于更高的分子检测成功率。必须进行进一步的研究以验证本研究的结果。
结果：什么是已知的，什么是新的？含义是什么，现在应该改变什么？
